Chronic limb-threatening Ischemia (CLTI), also known as Critical Limb Ischemia (CLI), is an advanced stage of peripheral artery disease (PAD). It is defined as ischemic rest pain, arterial insufficiency ulcers, and gangrene. The latter two conditions are jointly referred to as tissue loss, reflecting the development of surface damage to the limb tissue due to the most severe stage of ischemia.
The symptoms of ischemia depend upon how quickly the blood flow is interrupted and where it occurs. In the limbs, early symptoms of ischemia may include claudication (pain, burning, or cramping in the muscles with exercise that goes away with rest). This can progress over time to CLI, the reduction of blood flow to the affected extremity that results in severe pain or tissue loss.
Get FREE sample copy at:
The Critical Limb Ischemia market report also covers emerging drugs, current treatment practices, Critical Limb Ischemia market share of the individual therapies, current and forecasted Critical Limb Ischemia Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Critical Limb Ischemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Critical Limb Ischemia Market Key Facts
Eight to ten million Americans suffer from the arterial occlusive disease, leading to approximately 500–1,000 new cases of chronic limb ischemia per million people per year. The prevalence of critical limb ischemia is 12% in the adult population, with men affected slightly more than women. This prevalence is age-dependent as well, with nearly 20% of adults age 70 and older carrying a diagnosis of critical limb ischemia (Davies et. al., 2012).
As per the study conducted by Steve Duff et. al. titled “The burden of critical limb ischemia: a review of recent literature” CLI prevalence in the US adult population aged 40 or older is estimated to be 1.28%. With approximately 156 million US citizens in this age category, this prevalence estimate translates to approximately 2 million total CLI patients in the United States (2019).
According to DelveInsight’s findings, males are affected more as compared to females, in case of Critical Limb Ischemia.
Key Benefits of Critical Limb Ischemia Market Report
Critical Limb Ischemia market report provides an in-depth analysis of Critical Limb Ischemia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Critical Limb Ischemia market report will help in developing business strategies by understanding the Critical Limb Ischemia Market trends & developments, key players and future market competition that will shape and drive the Critical Limb Ischemia market in the upcoming years.
The Critical Limb Ischemia market report covers Critical Limb Ischemia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Critical Limb Ischemia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Critical Limb Ischemia Market
Critical Limb Ischemia market size is expected to increase during the forecast period owing to the increased research and development activities and increased patient pool in 7MM.
The Critical Limb Ischemia market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Critical Limb Ischemia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Critical Limb Ischemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Critical Limb Ischemia Epidemiology
The Critical Limb Ischemia epidemiology section covers insights about historical and current Critical Limb Ischemia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Critical Limb Ischemia Drugs Uptake and Key Market Players
The Critical Limb Ischemia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Critical Limb Ischemia market or expected to get launched in the market during the study period. The analysis covers Critical Limb Ischemia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Critical Limb Ischemia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world.
Critical Limb Ischemia companies
Libella Gene Therapeutics
Critical Limb Ischemia therapies covered in the report include:
And many more
Table of Content
1. Key Insights
2. Executive Summary
3. Critical Limb Ischemia Competitive Intelligence Analysis
4. Critical Limb Ischemia Market Overview at a Glance
5. Critical Limb Ischemia Disease Background and Overview
6. Critical Limb Ischemia Patient Journey
7. Critical Limb Ischemia Epidemiology and Patient Population
8. Critical Limb Ischemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Critical Limb Ischemia Unmet Needs
10. Key Endpoints of Critical Limb Ischemia Treatment
11. Critical Limb Ischemia Marketed Products
12. Critical Limb Ischemia Emerging Therapies
13. Critical Limb Ischemia Seven Major Market Analysis
14. Attribute Analysis
15. Critical Limb Ischemia Market Outlook (7 major markets)
16. Critical Limb Ischemia Access and Reimbursement Overview
17. KOL Views on the Critical Limb Ischemia Market.
18. Critical Limb Ischemia Market Drivers
19. Critical Limb Ischemia Market Barriers
21. DelveInsight Capabilities
Critical Limb Ischemia Epidemiology Forecast
DelveInsight’s Critical Limb Ischemia – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Critical Limb Ischemia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Critical Limb Ischemia Pipeline Insights
Critical Limb Ischemia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Critical Limb Ischemia market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd. 2432
City: Las Vegas
Country: United States